Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (369)	5/11/1999 3:24:00 PM
From: scaram(o)uche	Respond to of 3158

>> Wouldn't you pay a premium for this? << Just spit coffee on my keyboard when I came to this. Will gain my composure in time to go get the kids.

To: RWReeves who wrote (369)	5/11/1999 4:12:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 3158

Sounds to me like they will return only cash to the shareholders. The HQL portfolio at year end (latest I could find) was actually pretty reasonable, with SEPR the biggest holding. About 20% is in private companies, most of which I haven't heard of. Don't know how they value them, but given the state of the IPO market for biotechs they can't be worth much (except maybe Tularik?). Actually HQL could be a pretty reasonable short-term play based solely on the 25% discount shrinking. Peter